Active Ingredient History
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It works by decreasing the production of certain hormones, which reduces testosterone levels in the body. Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone. Triptorelin is indicated for the palliative treatment of advanced prostate cancer. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenomyosis (Phase 3)
Alkylating Agents (Phase 2/Phase 3)
Breast Neoplasms (Phase 3)
Castration (Phase 3)
Clomiphene (Phase 4)
Deficiency Diseases (Phase 1)
Drug-Related Side Effects and Adverse Reactions (Phase 2/Phase 3)
Embryo Transfer (Phase 4)
Endometriosis (Phase 4)
Fatigue (Phase 3)
Fatty Liver (Phase 4)
Female Urogenital Diseases (Phase 2)
Fertility (Phase 4)
Fertility Preservation (Phase 2/Phase 3)
Fertilization in Vitro (Phase 4)
Gender Dysphoria (Phase 4)
Gonadal Disorders (Phase 1)
Gonadotropin-Releasing Hormone (Phase 4)
Growth and Development (Phase 4)
Healthy Volunteers (Phase 2/Phase 3)
HIV Infections (Phase 2)
Hormones (Phase 2)
Hyperprolactinemia (Phase 1)
Hypogonadism (Phase 4)
Infertility (Phase 4)
Infertility, Female (Phase 4)
Kallmann Syndrome (Phase 1)
Lupus Erythematosus, Systemic (Phase 2)
Lymphoma (Phase 2/Phase 3)
Metabolic Syndrome (Phase 4)
Mifepristone (Early Phase 1)
Neoadjuvant Therapy (Phase 2/Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 2/Phase 3)
Osteoporosis (Phase 3)
Osteosarcoma (Phase 2/Phase 3)
Ovarian Diseases (Phase 3)
Ovarian Hyperstimulation Syndrome (Phase 4)
Polycystic Ovary Syndrome (Phase 4)
Primary Ovarian Insufficiency (Phase 4)
Prostate (Phase 2)
Prostatic Neoplasms, Castration-Resistant (Phase 2/Phase 3)
Puberty, Precocious (Phase 4)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2/Phase 3)
Sarcoma, Ewing (Phase 2/Phase 3)
Sleep Wake Disorders (Phase 3)
Sperm Injections, Intracytoplasmic (Phase 4)
Tendon Injuries (Phase 4)
Uterine Diseases (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue